AstraZeneca’s Tagrisso plus chemotherapy improves overall survival in EGFR-mutated advanced lung cancer
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
Longer-term follow up in the FLAURA2 Phase III trial confirms the favourable benefit-risk profile of this combination
Reblozyl is a standard of care for the first-line treatment of anemia without previous erythropoiesis stimulating agent use
The transaction, approved by both companies' boards of directors, is expected to close by the end of the first quarter of 2026
New platform powered by Opentrons expands lab automation to accelerate scientific discovery
In collaboration with the Gates Foundation, Merck advances MK-8527 pre-exposure prophylaxis (PrEP) clinical trials globally
Ukhade brings deep expertise in large-scale infrastructure planning, cross-functional leadership, and project innovation.
The company’s largest center for medical device applications, serving the entire Asian market
To streamline complex medical writing workflows with GenAI
IGI partners with AbbVie and grants exclusive rights to globally develop, manufacture, and commercialize ISB 2001 across North America, Europe, Japan, and Greater China
Subscribe To Our Newsletter & Stay Updated